Cardiovascular effects of fingolimod: Relevance, detection and approach | Zendy

Carlos Aguíar | Zendy; Sónia Batista | Zendy; Ricardo Pacheco | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cardiovascular effects of fingolimod: Relevance, detection and approach

Author(s) -

Carlos Aguíar,

Sónia Batista,

Ricardo Pacheco

Publication year - 2015

Publication title -

revista portuguesa de cardiologia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.266

H-Index - 26

eISSN - 2174-2030

pISSN - 0870-2551

DOI - 10.1016/j.repc.2014.11.012

Subject(s) - fingolimod , relevance (law) , medicine , computer science , multiple sclerosis , political science , psychiatry , law

Fingolimod, a structural analogue of sphingosine, is the first oral treatment available for multiple sclerosis. The presence of sphingosine-1-phosphate receptors in the sinus and atrioventricular nodes, myocardial cells, endothelial cells and arterial smooth muscle cells is responsible for fingolimod's cardiovascular effects. We provide a comprehensive review of the mechanisms of these effects and characterize their clinical relevance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research